Free Trial
NASDAQ:TRML

Tourmaline Bio (TRML) Stock Price, News & Analysis

Tourmaline Bio logo
$21.76 -0.37 (-1.67%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$21.80 +0.04 (+0.21%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Tourmaline Bio Stock (NASDAQ:TRML)

Key Stats

Today's Range
$21.16
$22.34
50-Day Range
$15.32
$23.34
52-Week Range
$11.56
$29.79
Volume
226,846 shs
Average Volume
188,810 shs
Market Capitalization
$558.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.33
Consensus Rating
Buy

Company Overview

Tourmaline Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
31st Percentile Overall Score

TRML MarketRank™: 

Tourmaline Bio scored higher than 31% of companies evaluated by MarketBeat, and ranked 766th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tourmaline Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Tourmaline Bio has only been the subject of 2 research reports in the past 90 days.

  • Read more about Tourmaline Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Tourmaline Bio are expected to decrease in the coming year, from ($3.02) to ($3.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Tourmaline Bio is -6.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Tourmaline Bio is -6.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Tourmaline Bio has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Tourmaline Bio's valuation and earnings.
  • Percentage of Shares Shorted

    18.39% of the float of Tourmaline Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Tourmaline Bio has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Tourmaline Bio has recently increased by 2.38%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Tourmaline Bio does not currently pay a dividend.

  • Dividend Growth

    Tourmaline Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    18.39% of the float of Tourmaline Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Tourmaline Bio has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Tourmaline Bio has recently increased by 2.38%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Tourmaline Bio has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Tourmaline Bio this week, compared to 3 articles on an average week.
  • Search Interest

    6 people have searched for TRML on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Tourmaline Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.00% of the stock of Tourmaline Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    91.89% of the stock of Tourmaline Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Tourmaline Bio's insider trading history.
Receive TRML Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tourmaline Bio and its competitors with MarketBeat's FREE daily newsletter.

TRML Stock News Headlines

BMO Capital Remains a Buy on Tourmaline Bio (TRML)
Tourmaline Bio Inc News (TRML) - Investing.com
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
TRML - Tourmaline Bio Inc Dividends - Morningstar
TRML - Tourmaline Bio Inc Executives - Morningstar
See More Headlines

TRML Stock Analysis - Frequently Asked Questions

Tourmaline Bio's stock was trading at $20.28 on January 1st, 2025. Since then, TRML stock has increased by 7.3% and is now trading at $21.76.

Tourmaline Bio, Inc. (NASDAQ:TRML) issued its quarterly earnings results on Friday, May, 2nd. The company reported ($0.89) earnings per share for the quarter, beating the consensus estimate of ($0.91) by $0.02.

Tourmaline Bio's top institutional investors include Wesbanco Bank Inc. (0.10%), Y Intercept Hong Kong Ltd (0.09%) and AlphaQuest LLC (0.01%). Insiders that own company stock include Mark Mcdade, Parvinder Thiara, Aaron Kantoff and Sandeep Chidambar Kulkarni.
View institutional ownership trends
.

Shares of TRML stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tourmaline Bio investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

Last Earnings
5/02/2025
Today
8/01/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TRML
Previous Symbol
NASDAQ:TRML
CIK
1827506
Web
N/A
Fax
N/A
Employees
44
Year Founded
N/A

Price Target and Rating

High Price Target
$70.00
Low Price Target
$25.00
Potential Upside/Downside
+123.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.21)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$73.21 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-26.75%
Return on Assets
-26.11%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
33.87
Quick Ratio
33.87

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$11.71 per share
Price / Book
1.88

Miscellaneous

Outstanding Shares
25,680,000
Free Float
22,346,000
Market Cap
$566.24 million
Optionable
Optionable
Beta
2.00
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:TRML) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners